MedTrace Logo

Efficacy and Safety of Finerenone in Heart Failure With Reduced Ejection Fraction

NCT05974566 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2023-08-03

No results posted yet for this study

Summary

Finerenone is a new selective nonsteroidal mineral corticoid receptor antagonist (MRA), nowadays it's widely used in type 2 diabetes (T2DM) patients with chronic kidney disease (CKD), the newest trial shows finerenone improve the cardiovascular outcomes among patients with T2DM and CKD especially reduce the risk of hospitalization for heart failure. In patients with diabetic nephropathy, finerenone resulted in lower risks of CKD progression and cardiovascular events. Finerenone shows great potential therapeutic effect in chronic heart failure (CHF) patients with or without T2DM and CKD compared to eplerenone, but there is still no real world study on finerenone in patients with heart failure with reduced ejection fraction (HFrEF) and it's unclear about the effect of finerenone in CHF patients without T2DM and CKD. The investigators will conduct a study to demonstrate the efficacy and safety of finerenone in HFrEF patients compared to other MRAs.

Conditions

  • Heart Failure With Reduced Ejection Fraction
  • Diabetes Mellitus
  • Diabetic Nephropathies

Sponsors & Collaborators

  • Chongqing Medical University

    lead OTHER

Principal Investigators

  • Dongying Zhang, PhD · First Affiliated Hospital of Chongqing Medical University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-01
Primary Completion
2023-09-30
Completion
2023-10-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05974566 on ClinicalTrials.gov